...
首页> 外文期刊>Journal of Clinical Oncology >HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
【24h】

HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.

机译:Hodgkin Reed-Sternberg细胞的HLA II类表达是经典Hodgkin淋巴瘤的独立预后因素。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: The neoplastic Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL) are derived from B cells. The frequency of HLA class II downregulation and its effect on prognosis are unknown. PATIENTS AND METHODS: Immunohistochemistry results for HLA class II were evaluated in 292 primary cHL patients in a population-based approach. Patients were diagnosed between 1989 and 2000 in the northern part of the Netherlands. Median age at diagnosis was 38 years (range, 8 to 88 years); 63% had Ann Arbor stage I or II, 24% stage III, and 13% stage IV disease. Median follow-up was 7.1 years. For 168 patients, HLA genotype data were available. RESULTS: Lack of HLA class II cell-surface expression on HRS cells was observed in 41.4% and was more common in patients with extranodal disease, patients with Epstein-Barr virus-negative disease, and patients with HLA class I-negative HRS cells. Alleles of three microsatellite markers in the HLA class II region were associated with presence or absence of protein expression. In univariate analyses, lack of HLA class II expression coincided with adverse outcome (5-years failure free survival [FFS], 67% v 85%; P = .001; 5-years age and sex matched relative survival (RS), 80% v 90%; P = .027). This effect remained in multivariate analyses for FFS with a hazard ratio of 2.40 (95% CI, 1.45 to 3.98) and RS with a relative excess risk of death of 2.55 (95% CI, 1.22 to 5.31). CONCLUSION: Lack of membranous HLA class II expression by HRS cells in diagnostic lymph node specimens is an independent adverse prognostic factor in cHL.
机译:目的:经典霍奇金淋巴瘤(cHL)中的肿瘤性霍奇金里德-斯特恩伯格(HRS)细胞来源于B细胞。 HLA II类下调的频率及其对预后的影响尚不清楚。患者和方法:采用基于人群的方法对292名原发性cHL患者的HLA II类免疫组织化学结果进行了评估。在1989年至2000年之间,在荷兰北部诊断出患者。诊断时的中位年龄为38岁(范围8至88岁)。 63%的患者患有Ann Arbor I或II期,24%的III期和13%的IV期疾病。中位随访时间为7。1年。对于168例患者,可获得HLA基因型数据。结果:在HRS细胞上缺乏HLA II类细胞表面表达的比例为41.4%,在结外性疾病患者,爱泼斯坦-巴尔病毒阴性疾病的患者和HLA I类阴性HRS细胞的患者中更为常见。 HLA II类区域中的三个微卫星标记的等位基因与蛋白质表达的存在与否相关。在单因素分析中,缺乏HLA II类表达与不良结局同时发生(5年无故障生存期[FFS],67%对85%; P = .001; 5岁年龄和性别匹配的相对生存期(RS),80 %v 90%; P = .027)。在多因素分析中,FFS的风险比为2.40(95%CI,1.45至3.98),RS的相对过高死亡风险为2.55(95%CI,1.22至5.31)。结论:诊断性淋巴结标本中HRS细胞缺乏膜HLA II类表达是cHL的独立不良预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号